Overview: Imatinib Resistance Mutation TestIntroduction: The Imatinib Resistance Mutation Test detects mutations in the BCR-ABL gene to guide leukemia treatment, preventing relapse. Aligned with 2023 NCCN guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding treatment adjustments, optimizing therapy, and improving outcomes in molecular pathology for patients with chronic myeloid leukemia (CML).
Other Names: BCR-ABL Mutation Test, Imatinib Resistance Assay.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Imatinib resistance testing began in the 2000s with targeted therapy research for CML. PCR-based methods improved in the 2010s, enhancing treatment precision.
Purpose: Detects imatinib resistance mutations to guide leukemia treatment, prevents relapse, and evaluates patients with CML.
Test Parameters: 1. Imatinib Resistance Mutations
Pretest Condition: No fasting required. Collect whole blood, bone marrow, or saliva at any time. Report history of CML, treatment response, or relapse.
Specimen: 2-5 mL whole blood (EDTA), 2-5 mL bone marrow (EDTA), or 1-2 mL saliva (sterile container). Transport in a biohazard bag.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document CML history, imatinib use, treatment response, or relapse. Include current medications and recent symptoms.
Consent: Written consent required, detailing the tests purpose, treatment implications, and potential need for alternative therapies.
Procedural Considerations: Uses PCR to detect BCR-ABL mutations (e.g., T315I). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for CML treatment adjustment.
Factors Affecting Result Accuracy: Improper sample handling, contamination, or low DNA quality can affect results. Recent treatments may influence mutation detection.
Clinical Significance: Detected mutations indicate imatinib resistance, guiding alternative tyrosine kinase inhibitor therapy. Negative results suggest continued imatinib efficacy.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: BCR-ABL quantitative PCR, complete blood count, or bone marrow biopsy to assess CML status.
Test Limitations: Limited to BCR-ABL mutations; other resistance mechanisms may exist. Clinical correlation is needed.
References: NCCN CML Guidelines, 2023; Blood, Deininger MW, 2022.
